FDA Approves Companion Diagnostic for Colorectal Cancer Treatment
The FDA has approved a companion diagnostic for identifying BRAF V600E-mutant metastatic colorectal cancer patients eligible for encorafenib combination therapy.
The FDA has approved a companion diagnostic for identifying BRAF V600E-mutant metastatic colorectal cancer patients eligible for encorafenib combination therapy.
Labcorp has expanded its MRD testing portfolio with new personalized panels for breast and lung cancer and nationwide whole-genome MRD testing for stage III colon cancer, enabling earlier detection of recurrence via ctDNA analysis.
A longitudinal study finds blood-based biomarkers more sensitive than PET scans in detecting obesity's impact on Alzheimer's pathology.
The biotechnology company's integrated screening approach combines whole-genome sequencing, imaging, and multiple biomarker tests to enable early detection.
The new PCR test detects and quantifies hepatitis delta virus (HDV)-specific RNA in human EDTA plasma and serum.
Special issue explores advances in noninvasive prenatal screening, molecular diagnostics, and care disparities affecting perinatal outcomes.
The test is being developed to differentiate between adenoviral conjunctivitis, herpetic keratitis, and allergic conjunctivitis at the point of care.
The test measures two sugar alcohols to detect SORD-related neuropathy, which standard genetic tests sometimes miss.
Research finds lysophosphatidylcholines either promote or protect against disease depending on APOE ε4 gene status, with implications for personalized treatments.
The automated system uses ion exchange HPLC technology to deliver A1c results while detecting common hemoglobin variants.
The agreement aims to improve early detection and management of chronic kidney disease in underserved populations through integrated diagnostics and digital health solutions.
The Cystic Fibrosis Base assay has received IVDR accreditation, ensuring high standards for detecting cystic fibrosis mutations.
The eight-minute test also shortened hospital stays by nearly two days at Froedtert Hospital, reinforcing previous multi-site evidence.